NEXUS Biosystems Acquires Tecan Group's REMP Sample Management Business

POWAY, California, July 15, 2010 - NEXUS Biosystems, Inc., a leading innovator and worldwide provider of
automated sample management systems, today announced the signing of an
agreement to acquire REMP AG, a wholly-owned subsidiary of Tecan, as well as
other related assets. Under this agreement, NEXUS will acquire all activities
of Tecan's REMP(R) Sample Management business segment from Tecan. REMP,
based in Oberdiessbach, Switzerland, is a leading global provider of sample
management systems and related sample management devices, instruments and
consumables. In parallel with this transaction, Tecan and NEXUS plan to
collaborate on various additional product groups. The transaction should be
closed within the next 2 months.

John Lillig CEO of NEXUS Biosystems, commented: "We are delighted with
the opportunity to broaden our automated chemical and biological sample
management offerings with the acquisition of Tecan's REMP Sample Management
business. Together with our new colleagues from REMP, we look forward to
continuing to provide innovative and reliable sample management solutions for
our customers in the biopharmaceutical, biorepository, diagnostic, forensic,
agrochemical and genomic research centers throughout the world. The combined
NEXUS-REMP resources will strengthen our capabilities and ensure continuity
of first-class service and support for our customers as well as expand our
product offerings for the growing global sample management community. As a
key part of this opportunity we also look forward to furthering our
collaborations with our colleagues at Tecan."

Thomas Bachmann, CEO of Tecan, commented: "We are certain that the sale
of REMP to NEXUS Biosystems is the ideal solution. Our customers will benefit
from the strong global market and service presence and the unparalleled
innovation strength of the combined NEXUS-REMP entity in this industry
segment. At Tecan, we will increasingly focus resources on growth projects in
our Life Sciences core markets and actively expand our end-customer business
and our OEM activities."

Complementary products and markets

NEXUS Biosystems is one of the world's leading providers of automated
sample management systems and technologies for the biopharmaceutical,
biorepository and related research communities around the world. NEXUS'
majority investor is Telegraph Hill Partners, a life science and medical
products growth equity investment company based in San Francisco (California,
USA).

NEXUS and REMP complement one another, with NEXUS having strengths in
high speed, mid-size sample management systems and high performance
microtiter plates, while REMP is a leader in small and large size automated
sample management systems and high quality sample containers and consumables.
REMP has a strong customer base in Europe and Asia with a growing presence in
the USA, while NEXUS enjoys a strong position in the USA with a growing
presence in Europe and Asia.

About NEXUS Biosystems:

NEXUS Biosystems (www.nexusbio.com) is a leading innovator and worldwide
provider of enabling technologies and automated sample management systems for
pharmaceutical, biotech, biorepository, agrochemical and related research
institutions worldwide. NEXUS products include the Universal Store family of
automated ambient, -20 degrees C and -80 degrees C chemical and biological
sample management systems, the Aurora line of high performance microplates,
the XPeel microplate de-sealer, and the Crystal Farm line of protein
crystallization systems. NEXUS was founded in 2005, is headquartered in
Poway, CA, has a European subsidiary NEXUS Biosystems GmbH in Munich,
Germany, and has sales and distribution offices throughout the US, Europe and
Asia.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory
instruments and solutions in biopharmaceuticals, forensics, and clinical
diagnostics. The company specializes in the development, production and
distribution of instruments and automated workflow solutions for laboratories
in the life sciences sector. Its clients include pharmaceutical and
biotechnology companies, university research departments, forensic and
diagnostic laboratories. As an original equipment manufacturer, Tecan is also
a leader in developing and manufacturing OEM instruments and components that
are then distributed by partner companies. Founded in Switzerland in 1980,
the company has manufacturing, research and development sites in both Europe
and North America and maintains a sales and service network in 52 countries.
In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR
259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss
Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).

About Telegraph Hill Partners:

Telegraph Hill Partners, based in San Francisco, CA, is a private equity
investment firm specializing in life science and medical device businesses.
The firm partners with private companies that demonstrate strong financial
performance and innovative products or services. Additional information can
be found at www.telegraphhillpartners.com.

John Lillig, President, CEO, jlillig at nexusbio.com; or CharlesPowell, V. P. Commercial Operations, cpowell at nexusbio.com, both of NEXUS Biosystems; or Martin Braendle, Head of Corporate Communications & Investor Relations, investor at tecan.com, +41(0)44-922-84-30, or Fax, +41(0)44-922-88-89, of Tecan Group